Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K40/4255—Mesothelin [MSLN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/54—Pancreas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector

Application Number	Priority Date	Filing Date	Title
CN2013089979		2013-12-19
CN2014082610		2014-07-21
CN2014090509		2014-11-06
PCT/CN2014/094393WO2015090230A1 (en)	2013-12-19	2014-12-19	Human mesothelin chimeric antigen receptors and uses thereof

Publication Number	Publication Date
SG11201604815RAtrue SG11201604815RA (en)	2016-07-28

Family

ID=53402126

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201604815RASG11201604815RA (en)	2013-12-19	2014-12-19	Human mesothelin chimeric antigen receptors and uses thereof

Country Status (14)

Country	Link
US (4)	US10640569B2 (en)
EP (2)	EP3083964B1 (en)
JP (5)	JP6779785B2 (en)
CN (2)	CN106459989B (en)
AU (4)	AU2014366047B2 (en)
BR (1)	BR112016013187A2 (en)
CA (3)	CA3225453A1 (en)
ES (1)	ES2918501T3 (en)
IL (1)	IL245764A0 (en)
MX (1)	MX2016008076A (en)
RU (1)	RU2714902C2 (en)
SG (1)	SG11201604815RA (en)
TW (1)	TWI672379B (en)
WO (1)	WO2015090230A1 (en)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102685501B1 (en)	2013-02-20	2024-07-17	노파르티스 아게	Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
US9573988B2 (en)	2013-02-20	2017-02-21	Novartis Ag	Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
ES2769574T3 (en)	2013-03-15	2020-06-26	Michael C Milone	Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (en)	2013-03-16	2014-10-31	Novartis Ag	CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
CA3225453A1 (en)*	2013-12-19	2015-06-25	Novartis Ag	Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en)	2013-12-20	2024-06-05	Novartis AG	Regulatable chimeric antigen receptor
EP4303229A3 (en)	2014-01-21	2024-04-17	Novartis AG	Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
WO2015157252A1 (en)	2014-04-07	2015-10-15	BROGDON, Jennifer	Treatment of cancer using anti-cd19 chimeric antigen receptor
EP3685842B1 (en)	2014-06-06	2022-08-31	Memorial Sloan-Kettering Cancer Center	Mesothelin-targeted chimeric antigen receptors and uses thereof
AU2015292744C1 (en)	2014-07-21	2021-01-21	Novartis Ag	Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
WO2016014576A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Treatment of cancer using a cd33 chimeric antigen receptor
US11542488B2 (en)	2014-07-21	2023-01-03	Novartis Ag	Sortase synthesized chimeric antigen receptors
RU2741120C2 (en)	2014-07-21	2021-01-22	Новартис Аг	Treating cancer using a chimeric antigenic cll-1 receptor
EP3174546B1 (en)	2014-07-31	2019-10-30	Novartis AG	Subset-optimized chimeric antigen receptor-containing t-cells
RU2020117196A (en)	2014-08-19	2020-10-15	Новартис Аг	CHIMERIC ANTIGENIC RECEPTOR (CAR) AGAINST CD123 FOR USE IN THE TREATMENT OF MALIGNANT TUMORS
ES2891332T3 (en)	2014-09-17	2022-01-27	Novartis Ag	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN114107424A (en)	2014-10-08	2022-03-01	诺华股份有限公司	Biomarkers for predicting therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
WO2016090034A2 (en)	2014-12-03	2016-06-09	Novartis Ag	Methods for b cell preconditioning in car therapy
EP3230441A4 (en)	2014-12-12	2018-10-03	Voyager Therapeutics, Inc.	Compositions and methods for the production of scaav
US20190054117A1 (en)*	2014-12-19	2019-02-21	Novartis Ag	Dimerization switches and uses thereof
CA2972597A1 (en)	2014-12-29	2016-07-07	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
US11459390B2 (en)	2015-01-16	2022-10-04	Novartis Ag	Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
US11161907B2 (en)*	2015-02-02	2021-11-02	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
GB201503133D0 (en)	2015-02-24	2015-04-08	Ucl Business Plc And Syncona Partners Llp	Chimeric protein
PT3280729T (en)	2015-04-08	2022-08-01	Novartis Ag	Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
JP7114457B2 (en)	2015-04-17	2022-08-08	ザトラスティーズオブザユニバーシティオブペンシルバニア	Methods for Improving Efficacy and Growth of Chimeric Antigen Receptor-Expressing Cells
EP3286211A1 (en)	2015-04-23	2018-02-28	Novartis AG	Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US10434153B1 (en)	2015-05-20	2019-10-08	Kim Leslie O'Neill	Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
CN109476722A (en)	2015-07-21	2019-03-15	诺华股份有限公司	Methods for improving the efficacy and expansion of immune cells
US11667691B2 (en)	2015-08-07	2023-06-06	Novartis Ag	Treatment of cancer using chimeric CD3 receptor proteins
US11352439B2 (en)	2015-08-13	2022-06-07	Kim Leslie O'Neill	Macrophage CAR (MOTO-CAR) in immunotherapy
GB201514874D0 (en)	2015-08-20	2015-10-07	Autolus Ltd	Cell
CN106467573B (en)	2015-08-21	2021-05-25	佧珐药业有限公司	Anti-mesothelin fully human antibody and immune effector cells targeting mesothelin
EP3340998B1 (en)	2015-08-28	2023-01-11	The Trustees of the University of Pennsylvania	Methods and compositions for cells expressing a chimeric intracellular signaling molecule
US11890301B2 (en)	2015-08-28	2024-02-06	The Trustees Of The University Of Pennsylvania	Methods and compositions for cells expressing a chimeric intracellular signaling molecule
US11747346B2 (en)	2015-09-03	2023-09-05	Novartis Ag	Biomarkers predictive of cytokine release syndrome
JP6821688B2 (en)	2015-10-09	2021-01-27	ミルテニー・バイオテク・テクノロジー・インコーポレイテッドＭｉｌｔｅｎｙｉＢｉｏｔｅｃＴｅｃｈｎｏｌｏｇｙ，Ｉｎｃ．	Chimeric antigen receptor and usage
NZ782857A (en)	2015-12-04	2025-08-29	Novartis Ag	Compositions and methods for immunooncology
EP3393504B1 (en)	2015-12-22	2025-09-24	Novartis AG	Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
JP2019500874A (en)	2015-12-28	2019-01-17	ノバルティスアーゲー	Method for producing chimeric antigen receptor-expressing cells
EP3397756B1 (en)	2015-12-30	2023-03-08	Novartis AG	Immune effector cell therapies with enhanced efficacy
EP3412149A4 (en)*	2016-02-01	2019-09-18	Green Cross Lab Cell Corporation	MEDIUM COMPOSITION FOR CRYOPRESERVATION OF CELLS AND USE THEREOF
BR112018067679A2 (en)*	2016-03-04	2019-01-15	Novartis Ag	cells expressing multiple chimeric antigen receptor (car) molecules and their use
WO2017165683A1 (en)	2016-03-23	2017-09-28	Novartis Ag	Cell secreted minibodies and uses thereof
AU2017250304B2 (en)	2016-04-15	2023-08-17	Novartis Ag	Compositions and methods for selective protein expression
US11400116B2 (en)*	2016-05-06	2022-08-02	The Regents Of The University Of California	Systems and methods for targeting cancer cells
WO2017214050A1 (en)*	2016-06-08	2017-12-14	The Board Of Trustees Of The Leland Stanford Junior University	Detection of pancreatic cancer with an engineered anti-thy1 single-chain antibody
WO2018001241A1 (en)*	2016-06-28	2018-01-04	北京百奥赛图基因生物技术有限公司	Method for constructing pd-1 gene-modified humanized animal model and use thereof
WO2018012895A1 (en)*	2016-07-14	2018-01-18	주식회사 큐로셀	Immune cell surmounting immune checkpoint and pharmaceutical composition containing same immune cell
KR101897464B1 (en)*	2016-07-14	2018-09-13	주식회사 큐로셀	Immune cell overcoming immune checkpoint signaling and pharmaceutical composition comprising said immune cell
CN110461315B (en)*	2016-07-15	2025-05-02	诺华股份有限公司	Treatment and prevention of cytokine release syndrome using chimeric antigen receptors in combination with kinase inhibitors
IL264486B2 (en)	2016-07-28	2025-04-01	Novartis Ag	Combination therapies of chimeric antigen receptors and pd-1 inhibitors
US20190161542A1 (en)	2016-08-01	2019-05-30	Novartis Ag	Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
AU2017308473B2 (en)*	2016-08-12	2021-08-19	Toolgen Incorporated	Manipulated immunoregulatory element and immunity altered thereby
CN107840891A (en)*	2016-09-19	2018-03-27	上海吉倍生物技术有限公司	The anti-MSLN antibody of high-affinity and its application
WO2018064387A1 (en)	2016-09-28	2018-04-05	Novartis Ag	Porous membrane-based macromolecule delivery system
MX2019003899A (en)*	2016-10-07	2019-08-14	Tcr2 Therapeutics Inc	Compositions and methods for t-cell receptors reprogramming using fusion proteins.
EP3523331A1 (en)	2016-10-07	2019-08-14	Novartis AG	Chimeric antigen receptors for the treatment of cancer
CN107058315B (en)*	2016-12-08	2019-11-08	上海优卡迪生物医药科技有限公司	Knockdown of human PD-1 siRNA, recombinant expression CAR-T vector and its construction method and application
CN107286247B (en)*	2016-12-28	2019-09-03	时力生物科技（北京）有限公司	The Dendritic Cells and application thereof of Chimeric antigen receptor modification containing anti-mesothelin single-chain antibody
EP4183798A1 (en)*	2017-01-09	2023-05-24	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-mesothelin immunotherapy
EP3574005B1 (en)	2017-01-26	2021-12-15	Novartis AG	Cd28 compositions and methods for chimeric antigen receptor therapy
JP2020506700A (en)	2017-01-31	2020-03-05	ノバルティスアーゲー	Cancer treatment using multispecific chimeric T cell receptor protein
EA201992232A1 (en)	2017-03-22	2020-05-14	Новартис Аг	COMPOSITIONS AND METHODS FOR IMMUNOUNCOLOGY
EP3388073A1 (en)*	2017-04-12	2018-10-17	polybliocept GmbH	Targeting mesothelin in brain cancer
CN109790518A (en)*	2017-05-08	2019-05-21	中国科学院动物研究所	Modified T cell, preparation method and the usage
CN118389601A (en)*	2017-05-08	2024-07-26	株式会社图尔金	Artificially manipulated immune cells
KR20200005655A (en)*	2017-05-15	2020-01-15	더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈	Non-cistronic Chimeric Antigen Receptors and Uses thereof
US10415017B2 (en)	2017-05-17	2019-09-17	Thunder Biotech, Inc.	Transgenic macrophages, chimeric antigen receptors, and associated methods
EP3624834A1 (en)*	2017-05-17	2020-03-25	Thunder Biotech Inc.	Transgenic macrophages, chimeric antigen receptors, and associated methods
CN109306014B (en)*	2017-07-27	2022-04-12	上海细胞治疗研究院	A chimeric antigen receptor-modified T cell targeting mesothelin and use thereof
CA3071649A1 (en)	2017-08-02	2019-02-07	Lilac Solutions, Inc.	Ion exchange system for lithium extraction
CN109553686A (en)*	2017-09-26	2019-04-02	南京安吉生物科技有限公司	The novel regulatable double Chimeric antigen receptor T cells of one kind and its construction method and application
CN109586842B (en)*	2017-09-29	2022-10-11	北京紫光展锐通信技术有限公司	PDCCH configuration method and device, decoding method and device, medium and equipment
CN109593721B (en)*	2017-09-30	2022-11-01	亘喜生物科技（上海）有限公司	Engineered immune cells targeting human mesothelin with suicide gene switch
WO2019072241A1 (en)	2017-10-13	2019-04-18	Beijing Biocytogen Co., Ltd	Genetically modified non-human animal with human or chimeric pd-1
MX2020004013A (en)	2017-10-18	2021-01-08	Novartis Ag	Compositions and methods for selective protein degradation.
US20200370012A1 (en)	2017-10-25	2020-11-26	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
JP6339283B1 (en)*	2017-10-31	2018-06-06	国立大学法人岡山大学	DNA, polypeptide, anti-mesothelin antibody, tumor imaging agent and complex
IL275567B2 (en)*	2017-12-27	2024-03-01	Takeda Pharmaceuticals Co	Nucleic acid-containing lipid nano-particle and use thereof
CN109971717B (en)*	2017-12-28	2023-06-20	上海细胞治疗研究院	T cells co-expressing CD40 antibody and mesothelin specific chimeric antigen receptor and uses thereof
CN109971714B (en)*	2017-12-28	2023-06-20	上海细胞治疗研究院	Chimeric antigen receptor modified T cells from PD-1 antibody expression and targeting mesothelin and uses thereof
WO2019136432A1 (en)	2018-01-08	2019-07-11	Novartis Ag	Immune-enhancing rnas for combination with chimeric antigen receptor therapy
WO2019138354A1 (en)*	2018-01-12	2019-07-18	Curocell Inc.	Enhanced immune cells using dual shrna and composition including the same
CA3090249A1 (en)	2018-01-31	2019-08-08	Novartis Ag	Combination therapy using a chimeric antigen receptor
WO2019160956A1 (en)	2018-02-13	2019-08-22	Novartis Ag	Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019175328A1 (en)	2018-03-14	2019-09-19	Imba - Institut Für Molekulare Biotechnologie Gmbh	Bh4pathwayactivationandusethereoffortreatingcancer
WO2019210153A1 (en)	2018-04-27	2019-10-31	Novartis Ag	Car t cell therapies with enhanced efficacy
WO2019213282A1 (en)	2018-05-01	2019-11-07	Novartis Ag	Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en)	2018-05-25	2021-07-15	Novartis Ag	Combination therapy with chimeric antigen receptor (car) therapies
US20210123075A1 (en)	2018-06-08	2021-04-29	Novartis Ag	Compositions and methods for immunooncology
KR20210020932A (en)	2018-06-13	2021-02-24	노파르티스 아게	BCMA chimeric antigen receptor and uses thereof
AR116109A1 (en)	2018-07-10	2021-03-31	Novartis Ag	DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
EP3833400A4 (en)*	2018-08-07	2022-06-15	Purdue Research Foundation	Rejuvenation of car t cell
EP3833446A2 (en)*	2018-08-10	2021-06-16	Sangamo Therapeutics France	New car constructs comprising tnfr2 domains
SG11202101773WA (en)	2018-08-29	2021-03-30	Nanjing Legend Biotech Co Ltd	Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
LT3844267T (en)	2018-08-31	2025-10-10		Methods of making chimeric antigen receptor-expressing cells
WO2020047449A2 (en)	2018-08-31	2020-03-05	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
CA3113058A1 (en)*	2018-09-20	2020-03-26	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-cd123 immunotherapy
US12331320B2 (en)	2018-10-10	2025-06-17	The Research Foundation For The State University Of New York	Genome edited cancer cell vaccines
CN119876276A (en)*	2018-10-18	2025-04-25	武田药品工业株式会社	T cell activation/proliferation method
AU2019402189B2 (en)	2018-12-20	2023-04-13	Novartis Ag	Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN109679871A (en)*	2019-01-08	2019-04-26	西北民族大学	A kind of method of PAM-SA immobilized microorganism degradation oily waste water
KR102070016B1 (en)*	2019-01-21	2020-01-29	(주)녹십자셀	Mesothelin-specific chimeric antigen receptor and T lymphocyte expressing this chimeric antigen receptor
FI3920939T3 (en)*	2019-02-08	2025-01-03	Biontech Cell & Gene Therapies Gmbh	Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers
CA3123519A1 (en)	2019-02-15	2020-08-20	Novartis Ag	Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7483732B2 (en)	2019-02-15	2024-05-15	ノバルティスアーゲー	3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3927371A1 (en)	2019-02-22	2021-12-29	Novartis AG	Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
JP7631211B2 (en)	2019-02-25	2025-02-18	ノバルティスアーゲー	Mesoporous silica particle compositions for viral delivery
US20220175833A1 (en)*	2019-03-07	2022-06-09	Children's Medical Center Corporation	Targeted delivery of immune-modulating vhh and vhh-fusion protein
CN110055269B (en)*	2019-03-20	2021-03-16	英威福赛生物技术有限公司	Human mesothelin chimeric antigen receptor, T cell thereof, preparation method and application thereof
WO2020210678A1 (en)	2019-04-12	2020-10-15	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en)	2019-04-24	2022-03-02	Novartis AG	Compositions and methods for selective protein degradation
GB201909283D0 (en)	2019-06-27	2019-08-14	Cancer Research Tech Ltd	Fusion proteins with enzyme activity
US20220348928A1 (en)*	2019-07-17	2022-11-03	Curocell Inc.	Enhanced immune cells using dual shrna and composition including the same
EP4031150A4 (en)*	2019-09-16	2023-11-01	The General Hospital Corporation	Cd70 targeted chimeric antigen receptor (car) t cells and uses thereof
AU2020358863A1 (en)	2019-10-03	2022-05-12	Celyntra Therapeutics Sa	CRISPR systems with engineered dual guide nucleic acids
EP4065157A1 (en)	2019-11-26	2022-10-05	Novartis AG	Cd19 and cd22 chimeric antigen receptors and uses thereof
IL293215A (en)	2019-11-26	2022-07-01	Novartis Ag	Chimeric antigen receptors that bind bcma and cd19 and their uses
US20230056470A1 (en)	2019-12-20	2023-02-23	Novartis Ag	Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021129927A1 (en)*	2019-12-23	2021-07-01	Biontech Cell & Gene Therapies Gmbh	Treatment with immune effector cells engineered to express an antigen receptor
CA3166356A1 (en)*	2019-12-23	2021-07-01	Cellectis	New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy
KR20220147109A (en)	2020-02-27	2022-11-02	노파르티스 아게	Methods for making chimeric antigen receptor-expressing cells
PH12022552283A1 (en)	2020-02-27	2024-01-22	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
KR20220150353A (en)	2020-03-05	2022-11-10	네오티엑스 테라퓨틱스 엘티디.	Methods and compositions for treating cancer using immune cells
CA3185455A1 (en)	2020-06-11	2021-12-16	Novartis Ag	Zbtb32 inhibitors and uses thereof
BR112022026202A2 (en)	2020-06-23	2023-01-17	Novartis Ag	DOSAGE REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-IL)PIPERIDINE-2,6-DIONE DERIVATIVES
CN116249716A (en)	2020-07-07	2023-06-09	康愈有限责任公司	MIC antibodies and binding agents and methods of use thereof
KR20230088333A (en)	2020-07-17	2023-06-19	인스틸 바이오 유케이 리미티드	Receptors that provide targeted costimulation for adoptive cell therapy
CN116134027B (en)	2020-08-03	2025-01-24	诺华股份有限公司	Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11795215B2 (en)*	2020-08-04	2023-10-24	Cellengene Inc	Anti-mesothelin chimeric antigen receptor specifically binding to mesothelin
KR20250140123A (en)	2020-08-20	2025-09-24	에이투 바이오쎄라퓨틱스, 인크.	Compositions and methods for treating mesothelin positive cancers
CN111948185B (en)*	2020-08-21	2023-03-21	中国药科大学	Sensor for instantly identifying development process of acute kidney injury based on two-dimensional amplification array mode, preparation method, application and use method
IL300489A (en)	2020-08-21	2023-04-01	Novartis Ag	Compositions and methods for in vivo generation of car expressing cells
GB202018554D0 (en)	2020-11-25	2021-01-06	Cancer Research Tech Ltd	Nucleic acid constructs and cells
TW202237638A (en)	2020-12-09	2022-10-01	日商武田藥品工業股份有限公司	Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
CN116635064A (en)	2020-12-18	2023-08-22	世纪治疗股份有限公司	A chimeric antigen receptor system with adaptive receptor specificity
US20240082306A1 (en)*	2021-02-03	2024-03-14	Bioheng Therapeutics Limited	Novel chimeric antigen receptor and use thereof
KR20240004245A (en)*	2021-02-10	2024-01-11	카테릭스 피티와이. 리미티드	Method and composition for generating stem cell-derived immune cells with improved function
CA3209863A1 (en)	2021-02-25	2022-09-01	Andrea BARGHETTI	Compositions and methods for targeting, editing, or modifying genes
TW202304979A (en)	2021-04-07	2023-02-01	瑞士商諾華公司	USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
TW202309294A (en)	2021-04-27	2023-03-01	瑞士商諾華公司	Viral vector production system
EP4333983A4 (en)*	2021-05-07	2025-07-30	Kiromic Biopharma Inc	MESOTHELIN ISOFORM-BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS THEREOF AND USES THEREOF
AU2022279862B2 (en)*	2021-05-26	2024-02-29	Cellengene Inc	Chimeric antigen receptor comprising anti-mesothelin scfv, and use thereof
EP4419672A2 (en)	2021-06-01	2024-08-28	Artisan Development Labs, Inc.	Compositions and methods for targeting, editing, or modifying genes
US11945876B2 (en)	2021-06-16	2024-04-02	Instil Bio (Uk) Limited	Receptors providing targeted costimulation for adoptive cell therapy
CA3223311A1 (en)	2021-06-18	2022-12-22	Andrea BARGHETTI	Compositions and methods for targeting, editing or modifying human genes
WO2023288278A1 (en)	2021-07-16	2023-01-19	Instil Bio (Uk) Limited	Chimeric molecules providing targeted costimulation for adoptive cell therapy
CN115989242A (en)*	2021-08-16	2023-04-18	上海优替济生生物医药有限公司	Mesothelin-targeted antibody, chimeric antigen receptor and application thereof
AR126838A1 (en)	2021-08-20	2023-11-22	Novartis Ag	METHODS FOR PREPARING CELLS THAT EXPRESS CHIMERIC ANTIGEN RECEPTORS
AU2022346040A1 (en)*	2021-09-17	2024-03-14	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric antigen receptors comprising interleukin-9 receptor signaling domain
MX2024003887A (en)	2021-10-14	2024-07-09	Arsenal Biosciences Inc	Immune cells having co-expressed shrnas and logic gate systems.
CN115991782A (en)*	2021-10-18	2023-04-21	普米斯生物技术(珠海)有限公司	Anti-mesothelin nanobody and use thereof
CN114276454B (en)*	2021-12-29	2022-12-20	华道(上海)生物医药有限公司	Anti-mesothelin nano antibody and application thereof
CN118574646A (en)*	2022-01-19	2024-08-30	上海优替济生生物医药有限公司	Circular RNA and use thereof
EP4486881A1 (en)	2022-03-01	2025-01-08	Celyntra Therapeutics SA	Composition and methods for transgene insertion
WO2023192195A1 (en)	2022-03-28	2023-10-05	Lilac Solutions, Inc.	Devices for efficient sorbent utilization in lithium extraction
WO2023214325A1 (en)	2022-05-05	2023-11-09	Novartis Ag	Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN119768177A (en)*	2022-07-13	2025-04-04	国立大学法人大阪大学	Preventive and/or therapeutic agent for tumor
EP4608983A1 (en)	2022-10-26	2025-09-03	Novartis AG	Lentiviral formulations
EP4613771A1 (en)*	2022-11-02	2025-09-10	Cellengene Inc	Chimeric antigen receptor with increased affinity for mesothelin and use thereof
CN116138212B (en)*	2023-01-11	2024-03-05	江苏省中医院	Method for preparing cytokine release syndrome mouse model and application
TW202500126A (en)	2023-05-24	2025-01-01	美商金橘生物科技公司	Heterocyclic compounds and uses thereof
WO2025059162A1 (en)	2023-09-11	2025-03-20	Dana-Farber Cancer Institute, Inc.	Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025090583A1 (en)*	2023-10-23	2025-05-01	The Regents Of The University Of California	Targeted delivery vehicles for endogenous cell engineering
CN117143825B (en)*	2023-11-01	2024-01-23	上海兴瑞一达生物科技有限公司	MSLN chimeric antigen receptor modified T cell and application thereof
WO2025145087A1 (en)*	2023-12-29	2025-07-03	Eureka Therapeutics, Inc.	Constructs targeting msln peptide/mhc complexes and uses thereof
WO2025184170A1 (en)	2024-02-27	2025-09-04	Overt Bio, Inc.	Methods and compositions for improving t cell function in an immunosuppressive environment
CN118667815B (en)*	2024-07-16	2025-02-14	宁夏大学	A nucleotide sequence targeting PRDM1 to improve bovine endometritis and its application

Family Cites Families (255)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR901228A (en)	1943-01-16	1945-07-20	Deutsche Edelstahlwerke Ag	Ring gap magnet system
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
GB2116183B (en)	1982-03-03	1985-06-05	Genentech Inc	Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
US5906936A (en)	1988-05-04	1999-05-25	Yeda Research And Development Co. Ltd.	Endowing lymphocytes with antibody specificity
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
EP1541682A3 (en)	1988-09-02	2005-07-06	Dyax Corp.	Generation and selection of recombinant varied binding proteins
US6303121B1 (en)	1992-07-30	2001-10-16	Advanced Research And Technology	Method of using human receptor protein 4-1BB
US6352694B1 (en)	1994-06-03	2002-03-05	Genetics Institute, Inc.	Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en)	1988-11-23	2003-03-18	Genetics Institute, Inc.	Methods for selectively stimulating proliferation of T cells
US6905680B2 (en)	1988-11-23	2005-06-14	Genetics Institute, Inc.	Methods of treating HIV infected subjects
US5858358A (en)	1992-04-07	1999-01-12	The United States Of America As Represented By The Secretary Of The Navy	Methods for selectively stimulating proliferation of T cells
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US5585362A (en)	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
WO1992020791A1 (en)	1990-07-10	1992-11-26	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
ES2113940T3 (en)	1990-12-03	1998-05-16	Genentech Inc	ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
JP3242916B2 (en)	1990-12-14	2001-12-25	セルジェネシス，インコーポレイティド	Chimeric chains for receptor-related signal transduction systems
US6319494B1 (en)	1990-12-14	2001-11-20	Cell Genesys, Inc.	Chimeric chains for receptor-associated signal transduction pathways
EP0575485A1 (en)	1991-03-01	1993-12-29	Dyax Corp.	Process for the development of binding mini-proteins
NZ241855A (en)	1991-03-07	1994-04-27	Gen Hospital Corp	Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor
US6004811A (en)	1991-03-07	1999-12-21	The Massachussetts General Hospital	Redirection of cellular immunity by protein tyrosine kinase chimeras
US7049136B2 (en)	1991-03-07	2006-05-23	The General Hospital Corporation	Redirection of cellular immunity by receptor chimeras
DE69233750D1 (en)	1991-04-10	2009-01-02	Scripps Research Inst	Libraries of heterodimeric receptors using phagemids
US5199942A (en)	1991-06-07	1993-04-06	Immunex Corporation	Method for improving autologous transplantation
DE4122599C2 (en)	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid for screening antibodies
GB9125768D0 (en)	1991-12-04	1992-02-05	Hale Geoffrey	Therapeutic method
IL104570A0 (en)	1992-03-18	1993-05-13	Yeda Res & Dev	Chimeric genes and cells transformed therewith
US8211422B2 (en)	1992-03-18	2012-07-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric receptor genes and cells transformed therewith
ATE452975T1 (en)	1992-08-21	2010-01-15	Univ Bruxelles	IMMUNOGLOBULINS WITHOUT LIGHT CHAINS
US5350674A (en)	1992-09-04	1994-09-27	Becton, Dickinson And Company	Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US7211259B1 (en)	1993-05-07	2007-05-01	Immunex Corporation	4-1BB polypeptides and DNA encoding 4-1BB polypeptides
WO1995014023A1 (en)	1993-11-19	1995-05-26	Abbott Laboratories	Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
JP3745772B2 (en)	1993-12-17	2006-02-15	ノバルティスアクチエンゲゼルシャフト	Rapamycin derivatives useful as immunosuppressants
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
ES2185705T3 (en)	1994-05-02	2003-05-01	Bernd Groner	BIFUNCTIONAL PROTEIN, PREPARATION AND USE.
US7175843B2 (en)	1994-06-03	2007-02-13	Genetics Institute, Llc	Methods for selectively stimulating proliferation of T cells
US5786464C1 (en)	1994-09-19	2012-04-24	Gen Hospital Corp	Overexpression of mammalian and viral proteins
US5712149A (en)	1995-02-03	1998-01-27	Cell Genesys, Inc.	Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en)	1995-02-06	2000-08-15	Cell Genesys, Inc.	Multispecific chimeric receptors
WO1996025953A1 (en)	1995-02-24	1996-08-29	The General Hospital Corporation	Redirection of cellular immunity by receptor chimeras
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
WO1996034096A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US7067318B2 (en)	1995-06-07	2006-06-27	The Regents Of The University Of Michigan	Methods for transfecting T cells
US6692964B1 (en)	1995-05-04	2004-02-17	The United States Of America As Represented By The Secretary Of The Navy	Methods for transfecting T cells
SK284529B6 (en)	1995-06-09	2005-05-05	Novartis Ag	Rapamycin derivatives, process of their preparation, pharmaceutical composition containing thereof and kit or package for use in immunosuppression, inflammation or infections
FR2736550B1 (en)	1995-07-14	1998-07-24	Sandoz Sa	PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLID DISPERSION COMPRISING A MACROLIDE AND A VEHICLE
GB9526131D0 (en)	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Recombinant chimeric receptors
US5874240A (en)	1996-03-15	1999-02-23	Human Genome Sciences, Inc.	Human 4-1BB receptor splicing variant
US6258823B1 (en)	1996-07-12	2001-07-10	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
US6111090A (en)	1996-08-16	2000-08-29	Schering Corporation	Mammalian cell surface antigens; related reagents
EP0920505B1 (en)	1996-08-16	2008-06-04	Schering Corporation	Mammalian cell surface antigens; related reagents
US6114148C1 (en)	1996-09-20	2012-05-01	Gen Hospital Corp	High level expression of proteins
CA2269738A1 (en)	1996-10-25	1998-05-07	Mitchell H. Finer	Targeted cytolysis of cancer cells
KR100643058B1 (en)	1996-12-03	2006-11-13	아브게닉스, 인크.	Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
ES2268763T3 (en)	1997-01-21	2007-03-16	The General Hospital Corporation	SELECTION OF PROTEINS USING ARN-PROTEIN FUSIONS.
DK0985039T3 (en)	1997-06-12	2008-06-09	Novartis Int Pharm Ltd	Artificial antibody polypeptides
GB9713473D0 (en)	1997-06-25	1997-09-03	Celltech Therapeutics Ltd	Biological products
US20030060444A1 (en)	1997-06-25	2003-03-27	Celltech Therapeutics, Ltd.	Cell activation process and reagents therefor
US6015815A (en)	1997-09-26	2000-01-18	Abbott Laboratories	Tetrazole-containing rapamycin analogs with shortened half-lives
TW557297B (en)	1997-09-26	2003-10-11	Abbott Lab	Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
CA2308114A1 (en)	1997-10-21	1999-04-29	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
JP2002502607A (en)	1998-02-09	2002-01-29	ジェネンテク・インコーポレイテッド	Novel tumor necrosis factor receptor homologs and nucleic acids encoding the same
DE69925909T2 (en)	1998-04-15	2006-05-11	Brigham & Women's Hospital, Inc., Boston	T-cell inhibiting receptor compositions and their use
GB9809658D0 (en)	1998-05-06	1998-07-01	Celltech Therapeutics Ltd	Biological products
CA2343156A1 (en)	1998-09-04	2000-03-16	Sloan-Kettering Institute For Cancer Research	Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6410319B1 (en)	1998-10-20	2002-06-25	City Of Hope	CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
JP2002541845A (en)	1999-04-16	2002-12-10	セルテックセラピューティックスリミテッド	Synthetic transmembrane component
IL147442A0 (en)	1999-07-12	2002-08-14	Genentech Inc	Promotion or inhibition of angiogenesis and cardiovscularization by tumor necrosis factor ligand/receptor homologs
DE60010098T2 (en)	1999-08-24	2005-03-31	Ariad Gene Therapeutics, Inc., Cambridge	28-EPIRAPALOGE
EP1235842A4 (en)	1999-10-15	2003-04-23	Univ Massachusetts	GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE
GB9925848D0 (en)	1999-11-01	1999-12-29	Celltech Therapeutics Ltd	Biological products
US6326193B1 (en)	1999-11-05	2001-12-04	Cambria Biosciences, Llc	Insect control agent
US6797514B2 (en)	2000-02-24	2004-09-28	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
US6867041B2 (en)	2000-02-24	2005-03-15	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
HK1047770A1 (en)	2000-02-24	2003-03-07	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
IL136511A0 (en)	2000-06-01	2001-06-14	Gavish Galilee Bio Appl Ltd	Genetically engineered mhc molecules
AU2001275474A1 (en)	2000-06-12	2001-12-24	Akkadix Corporation	Materials and methods for the control of nematodes
GB0025307D0 (en)	2000-10-16	2000-11-29	Celltech Chiroscience Ltd	Biological products
WO2002036142A2 (en)*	2000-11-03	2002-05-10	University Of Vermont And State Agricultural College	Compositions for inhibiting grb7
DE60122765D1 (en)	2000-11-07	2006-10-12	Hope City	CD19-SPECIFIC TARGETED IMMUNOCELLS
CN1294148C (en)	2001-04-11	2007-01-10	中国科学院遗传与发育生物学研究所	Single-stranded cyctic trispecific antibody
US7070995B2 (en)	2001-04-11	2006-07-04	City Of Hope	CE7-specific redirected immune cells
EP1392818A4 (en)	2001-04-30	2005-01-05	Hope City	CHIMERIC IMMUNORECTOR USE IN THE TREATMENT OF HUMAN CANCER
US20090257994A1 (en)	2001-04-30	2009-10-15	City Of Hope	Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en)	2001-04-30	2009-04-07	City Of Hope	Chimeric immunoreceptor useful in treating human gliomas
EP2281837B1 (en)	2001-08-10	2016-10-05	Aberdeen University	Antigen binding domains from fish
JP4578098B2 (en)	2001-10-01	2010-11-10	ダイアックス、コープ	Multi-chain eukaryotic display vectors and their use
US20030148982A1 (en)	2001-11-13	2003-08-07	Brenner Malcolm K.	Bi-spcific chimeric T cells
US7745140B2 (en)	2002-01-03	2010-06-29	The Trustees Of The University Of Pennsylvania	Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7638326B2 (en)	2002-01-03	2009-12-29	The Trustees Of The University Of Pennsylvania	Activation and expansion of T-cells using an engineered multivalent signaling platform
WO2003057171A2 (en)	2002-01-03	2003-07-17	The Trustees Of The University Of Pennsylvania	Activation and expansion of t-cells using an engineered multivalent signaling platform
DK1478648T3 (en)	2002-02-01	2014-07-28	Ariad Pharma Inc	PHOSPHORUS RELATIONS AND APPLICATIONS THEREOF
GB0208104D0 (en)	2002-04-09	2002-05-22	Univ Dundee	Method
US7446190B2 (en)	2002-05-28	2008-11-04	Sloan-Kettering Institute For Cancer Research	Nucleic acids encoding chimeric T cell receptors
US20040047858A1 (en)	2002-09-11	2004-03-11	Blumberg Richard S.	Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
US7488802B2 (en)	2002-12-23	2009-02-10	Wyeth	Antibodies against PD-1
US20050129671A1 (en)	2003-03-11	2005-06-16	City Of Hope	Mammalian antigen-presenting T cells and bi-specific T cells
JP4638876B2 (en)	2003-05-23	2011-02-23	ワイス	GITR ligand, GITR ligand-related molecule and antibody and use thereof
JP5026072B2 (en)	2003-07-01	2012-09-12	イミューノメディクス、インコーポレイテッド	Multispecific carrier of bispecific antibody
US20050048054A1 (en)	2003-07-11	2005-03-03	Shino Hanabuchi	Lymphocytes; methods
WO2005019429A2 (en)	2003-08-22	2005-03-03	Potentia Pharmaceuticals, Inc.	Compositions and methods for enhancing phagocytosis or phagocyte activity
US20050113564A1 (en)	2003-11-05	2005-05-26	St. Jude Children's Research Hospital	Chimeric receptors with 4-1BB stimulatory signaling domain
US7435596B2 (en)	2004-11-04	2008-10-14	St. Jude Children's Research Hospital, Inc.	Modified cell line and method for expansion of NK cell
US7220755B2 (en)	2003-11-12	2007-05-22	Biosensors International Group, Ltd.	42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
JP2007518399A (en)	2003-12-02	2007-07-12	ジェンザイムコーポレイション	Compositions and methods for diagnosing and treating lung cancer
GB0409799D0 (en)	2004-04-30	2004-06-09	Isis Innovation	Method of generating improved immune response
EP1765988B1 (en)	2004-05-27	2017-09-20	The Trustees of The University of Pennsylvania	Novel artificial antigen presenting cells and uses therefor
EP1765402A2 (en)	2004-06-04	2007-03-28	Duke University	Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
JP2008512352A (en)	2004-07-17	2008-04-24	イムクローンシステムズインコーポレイティド	Novel tetravalent bispecific antibody
WO2006036445A2 (en)	2004-09-24	2006-04-06	Trustees Of Dartmouth College	Chimeric nk receptor and methods for treating cancer
EP1827604B1 (en)	2004-12-10	2019-11-20	Peter MacCallum Cancer Institute	Methods and compositions for adoptive immunotherapy
PT2343320T (en)	2005-03-25	2018-01-23	Gitr Inc	Anti-gitr antibodies and uses thereof
CA3151350A1 (en)	2005-05-09	2006-11-16	E. R. Squibb & Sons, L.L.C.	Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
CA3201163A1 (en)	2005-07-01	2007-01-11	E. R. Squibb & Sons, L.L.C.	Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US20070036773A1 (en)	2005-08-09	2007-02-15	City Of Hope	Generation and application of universal T cells for B-ALL
EP2495257A3 (en)	2005-08-19	2012-10-17	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
EA024305B1 (en)	2005-10-07	2016-09-30	Экселиксис, Инк.	Phosphatidylinositol 3-kinase inhibitors and use thereof
WO2007133822A1 (en)	2006-01-19	2007-11-22	Genzyme Corporation	Gitr antibodies for the treatment of cancer
US20100105136A1 (en)	2006-10-09	2010-04-29	The General Hospital Corporation	Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
US20080131415A1 (en)	2006-11-30	2008-06-05	Riddell Stanley R	Adoptive transfer of cd8 + t cell clones derived from central memory cells
CA2682527C (en)	2007-03-30	2017-07-11	Memorial Sloan-Kettering Cancer Center	Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
CN102131828B (en)	2007-06-18	2015-06-17	默沙东有限责任公司	Antibody against human programmed death receptor PD-1
WO2009009116A2 (en)	2007-07-12	2009-01-15	Tolerx, Inc.	Combination therapies employing gitr binding molecules
US8359965B2 (en)	2007-09-17	2013-01-29	Oxford J Craig	Apparatus and method for broad spectrum radiation attenuation
CN101951946B (en)	2007-10-01	2014-12-10	百时美施贵宝公司	Human antibodies that bind mesothelin and uses thereof
EP2212350B1 (en)	2007-10-26	2013-08-28	Governing Council of the University of Toronto	Treating chronic viral infection by targetting TIM-3
US10059923B2 (en)	2008-01-30	2018-08-28	Memorial Sloan Kettering Cancer Center	Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
CN101970499B (en)	2008-02-11	2014-12-31	治疗科技公司	Monoclonal Antibodies for Cancer Therapy
JP2011512395A (en)	2008-02-21	2011-04-21	アストラゼネカアクチボラグ	Combination therapy 238
US8379824B2 (en)	2008-03-06	2013-02-19	At&T Intellectual Property I, Lp	Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
US8168757B2 (en)	2008-03-12	2012-05-01	Merck Sharp & Dohme Corp.	PD-1 binding proteins
EP2310508A1 (en)	2008-07-02	2011-04-20	Emergent Product Development Seattle, LLC	Tgf-b antagonist multi-target binding proteins
AR072999A1 (en)	2008-08-11	2010-10-06	Medarex Inc	HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
US20110223188A1 (en)	2008-08-25	2011-09-15	Solomon Langermann	Targeted costimulatory polypeptides and methods of use to treat cancer
EP2927240A1 (en)	2008-08-25	2015-10-07	Amplimmune, Inc.	Compositions of pd-1 antagonists and methods of use
ES2961498T3 (en)	2008-08-26	2024-03-12	Hope City	Method and compositions for enhanced performance of anti-tumor effect of T cells
WO2010030002A1 (en)	2008-09-12	2010-03-18	国立大学法人三重大学	Cell capable of expressing exogenous gitr ligand
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
PT4209510T (en)	2008-12-09	2024-04-02	Hoffmann La Roche	Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2389443B1 (en)	2009-01-23	2018-11-14	Roger Williams Hospital	Retroviral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
EP3192811A1 (en)	2009-02-09	2017-07-19	Université d'Aix-Marseille	Pd-1 antibodies and pd-l1 antibodies and uses thereof
SG173654A1 (en)	2009-02-23	2011-09-29	Glenmark Pharmaceuticals Sa	Humanized antibodies that bind to cd19 and their uses
EP2411416A1 (en)	2009-03-24	2012-02-01	The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services	Anti-mesothelin antibodies
CN102428085B (en)	2009-04-03	2015-07-15	维拉斯通股份有限公司	Pyrimidine-substituted purine compounds as kinase inhibitors
PL2424896T3 (en)	2009-04-30	2016-03-31	Tel Hashomer Medical Res Infrastructure & Services Ltd	Anti ceacam1 antibodies and methods of using same
ES2788869T3 (en)	2009-09-03	2020-10-23	Merck Sharp & Dohme	Anti-GITR antibodies
AU2010301042B2 (en)	2009-10-01	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2011059836A2 (en)	2009-10-29	2011-05-19	Trustees Of Dartmouth College	T cell receptor-deficient t cell compositions
GB0919054D0 (en)	2009-10-30	2009-12-16	Isis Innovation	Treatment of obesity
US8956828B2 (en)	2009-11-10	2015-02-17	Sangamo Biosciences, Inc.	Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
JP2013512251A (en)	2009-11-24	2013-04-11	アンプリミューン、インコーポレーテッド	Simultaneous inhibition of PD-L1 / PD-L2
EA022984B1 (en)	2009-12-29	2016-04-29	Эмерджент Продакт Дивелопмент Сиэтл, Ллс	Ron binding constructs and methods of use thereof
CN102134276A (en)*	2010-01-22	2011-07-27	上海抗体药物国家工程研究中心有限公司	Chimeric antibody resisting CTLA-4 (Cytotoxic T Lymphocyte Antigen)
WO2011097477A1 (en)	2010-02-04	2011-08-11	The Trustees Of The University Of Pennsylvania	Icos critically regulates the expansion and function of inflammatory human th17 cells
JP2013532153A (en)	2010-06-18	2013-08-15	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	Bispecific antibodies against TIM-3 and PD-1 for immunotherapy against chronic immune disease
CA2803900A1 (en)	2010-07-09	2012-01-12	Exelixis, Inc.	Combinations of kinase inhibitors for the treatment of cancer
CN103108873A (en)	2010-07-16	2013-05-15	皮拉马尔企业有限公司	Substituted imidazoquinoline derivatives as kinase inhibitors
US8945868B2 (en)	2010-07-21	2015-02-03	Sangamo Biosciences, Inc.	Methods and compositions for modification of a HLA locus
KR20140002649A (en)	2010-10-27	2014-01-08	베이롤 칼리지 오브 메드신	Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
US9233125B2 (en)	2010-12-14	2016-01-12	University Of Maryland, Baltimore	Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
BR112013014527A2 (en)*	2010-12-20	2017-03-07	Genentech Inc	isolated antibody, isolated nucleic acid, host cell, method for producing an antibody, immunoconjugate, pharmaceutical formulation, use of immunoconjugate, method for treating an individual who has mesothelin positive cancer, for inhibiting proliferation of a mesothelin positive cell, for detecting human mesothelin in a biological sample and for detecting mesothelin positive cancer
AU2012207356A1 (en)	2011-01-18	2013-08-01	The Trustees Of The University Of Pennsylvania	Compositions and methods for treating cancer
WO2012127464A2 (en)	2011-03-23	2012-09-27	Gavish-Galilee Bio Applications Ltd	Constitutively activated t cells for use in adoptive cell therapy
EP2689010B1 (en)	2011-03-23	2020-11-18	Fred Hutchinson Cancer Research Center	Method and compositions for cellular immunotherapy
EA201391449A1 (en)	2011-04-01	2014-03-31	Мемориал Слоан-Кеттеринг Кэнсер Сентер	ANTIBODIES AGAINST CYTOSOL PEPTIDES
DK2694640T3 (en)	2011-04-08	2017-11-20	Baylor College Medicine	REVERSION OF THE EFFECTS OF TUMOR MICRO-ENVIRONMENT USING CHEMICAL CYTOKIN RECEPTORS
PT2694549T (en)	2011-04-08	2018-11-22	Us Health	Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
US20130071414A1 (en)	2011-04-27	2013-03-21	Gianpietro Dotti	Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
US8841418B2 (en)	2011-07-01	2014-09-23	Cellerant Therapeutics, Inc.	Antibodies that specifically bind to TIM3
ES2990023T3 (en)	2011-07-25	2024-11-28	Nationwide Childrens Hospital Inc	Recombinant virus products and methods for inhibition of DUX4 expression
CN107266584B (en)	2011-07-29	2022-05-13	宾夕法尼亚大学董事会	Transducible co-stimulatory receptors
RU2636588C2 (en)	2011-08-11	2017-11-24	ИНТЕЛЛАЙКИН, ЭлЭлСи	Polymorphs of kinase inhibitor
WO2013033626A2 (en)	2011-08-31	2013-03-07	Trustees Of Dartmouth College	Nkp30 receptor targeted therapeutics
WO2013039954A1 (en)	2011-09-14	2013-03-21	Sanofi	Anti-gitr antibodies
SG11201400527XA (en)	2011-09-16	2014-04-28	Univ Pennsylvania	Rna engineered t cells for the treatment of cancer
WO2013040371A2 (en)	2011-09-16	2013-03-21	Baylor College Of Medicine	Targeting the tumor microenvironment using manipulated nkt cells
WO2013040577A1 (en)	2011-09-16	2013-03-21	The Research Foundation Of State University Of New York	Aptamers resistant to nucleocapsid degradation
WO2013054320A1 (en)	2011-10-11	2013-04-18	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
CA2851795C (en)	2011-10-20	2018-11-13	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-cd22 chimeric antigen receptors
WO2013063419A2 (en)*	2011-10-28	2013-05-02	The Trustees Of The University Of Pennsylvania	A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US10391126B2 (en)*	2011-11-18	2019-08-27	Board Of Regents, The University Of Texas System	CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
US9556271B2 (en)	2011-12-01	2017-01-31	The Brigham And Women's Hospital, Inc.	Anti-CEACAM1 recombinant antibodies for cancer therapy
IN2014DN07414A (en)	2012-02-22	2015-04-24	Univ Pennsylvania
WO2013126726A1 (en)*	2012-02-22	2013-08-29	The Trustees Of The University Of Pennsylvania	Double transgenic t cells comprising a car and a tcr and their methods of use
WO2013126720A2 (en)*	2012-02-22	2013-08-29	The Trustees Of The University Of Pennsylvania	Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing
EP2817331B1 (en)*	2012-02-22	2023-08-30	The Trustees of the University of Pennsylvania	Use of the cd2 signaling domain in second-generation chimeric antigen receptors
CA3084919A1 (en)*	2012-02-22	2013-08-29	The Trustees Of The University Of Pennsylvania	Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
CA2868121C (en)*	2012-03-23	2021-06-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-mesothelin chimeric antigen receptors
FI3597749T3 (en)	2012-05-25	2023-10-09	Univ California	METHODS AND COMPOSITIONS FOR RNA-DIRECTED MODIFICATION OF TARGET DNA AND RNA-DIRECTED MODULATION OF TRANSCRIPTION
KR20150029714A (en)	2012-07-13	2015-03-18	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	Enhancing activity of car t cells by co-introducing a bispecific antibody
US20160235787A1 (en)	2012-07-13	2016-08-18	The Trustees Of The University Of Pennsylvania	Epitope Spreading Associated with CAR T-Cells
AU2013289970A1 (en)	2012-07-13	2015-01-22	The Trustees Of The University Of Pennsylvania	Compositions and methods for regulating CAR T cells
KR102216083B1 (en)	2012-07-13	2021-02-17	더 트러스티스 오브 더 유니버시티 오브 펜실베니아	Use of cart19 to deplete normal b cells to induce tolerance
PT2872171T (en)	2012-07-13	2021-03-31	Univ Pennsylvania	TOXICITY MANAGEMENT FOR ANTITUMORAL CARS ACTIVITY
WO2014011996A1 (en)	2012-07-13	2014-01-16	The Trustees Of The University Of Pennsylvania	Methods of assessing the suitability of transduced t cells for administration
CA2916638C (en)	2012-07-31	2021-01-12	The Brigham And Women's Hospital, Inc.	Modulation of the immune response
CN102775500A (en)*	2012-08-03	2012-11-14	郑骏年	Chimeric antigen receptor iRGD-scFv (G250)-CD8-CD28-CD137-CD3zeta and application thereof
IL269270B (en)	2012-08-20	2022-07-01	Hutchinson Fred Cancer Res	Method and preparations for cellular immunotherapy
US9937205B2 (en)	2012-09-04	2018-04-10	The Trustees Of The University Of Pennsylvania	Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
US9416190B2 (en)	2012-09-27	2016-08-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Mesothelin antibodies and methods for eliciting potent antitumor activity
CN102875685B (en)*	2012-09-29	2013-12-25	郑骏年	Chimeric antigen receptor hFVIIL-CD8-OX40-CD3zeta and application thereof
US9365641B2 (en)	2012-10-01	2016-06-14	The Trustees Of The University Of Pennsylvania	Compositions and methods for targeting stromal cells for the treatment of cancer
US10117896B2 (en)	2012-10-05	2018-11-06	The Trustees Of The University Of Pennsylvania	Use of a trans-signaling approach in chimeric antigen receptors
JP6356134B2 (en)	2012-10-12	2018-07-11	ザブリガムアンドウィメンズホスピタルインコーポレイテッドＴｈｅＢｒｉｇｈａｍａｎｄＷｏｍｅｎ’ｓＨｏｓｐｉｔａｌ，Ｉｎｃ．	Enhanced immune response
JP2016505256A (en)	2012-12-12	2016-02-25	ザ・ブロード・インスティテュート・インコーポレイテッ	CRISPR-Cas component system, method and composition for sequence manipulation
US8697359B1 (en)	2012-12-12	2014-04-15	The Broad Institute, Inc.	CRISPR-Cas systems and methods for altering expression of gene products
ES2576126T3 (en)	2012-12-12	2016-07-05	The Broad Institute, Inc.	Modification by genetic technology and optimization of improved enzyme systems, methods and compositions for sequence manipulation
CN103145849B (en)	2013-02-18	2014-06-11	冯振卿	Chimeric antigen receptor and use thereof
US9573988B2 (en)	2013-02-20	2017-02-21	Novartis Ag	Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
KR102685501B1 (en)	2013-02-20	2024-07-17	노파르티스 아게	Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
ES2769574T3 (en)	2013-03-15	2020-06-26	Michael C Milone	Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (en)	2013-03-16	2014-10-31	Novartis Ag	CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
CA3225453A1 (en)	2013-12-19	2015-06-25	Novartis Ag	Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en)	2013-12-20	2024-06-05	Novartis AG	Regulatable chimeric antigen receptor
EP4303229A3 (en)	2014-01-21	2024-04-17	Novartis AG	Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
US20170081411A1 (en)	2014-03-15	2017-03-23	Novartis Ag	Regulatable chimeric antigen receptor
JP2017513818A (en)	2014-03-15	2017-06-01	ノバルティスアーゲー	Treatment of cancer using chimeric antigen receptors
WO2015157252A1 (en)	2014-04-07	2015-10-15	BROGDON, Jennifer	Treatment of cancer using anti-cd19 chimeric antigen receptor
US11542488B2 (en)*	2014-07-21	2023-01-03	Novartis Ag	Sortase synthesized chimeric antigen receptors
JP2017528433A (en)	2014-07-21	2017-09-28	ノバルティスアーゲー	Low immunoenhancing dose of mTOR inhibitor and CAR combination
RU2741120C2 (en)	2014-07-21	2021-01-22	Новартис Аг	Treating cancer using a chimeric antigenic cll-1 receptor
US20170274014A1 (en)	2014-07-21	2017-09-28	Jennifer Brogdon	Combinations of low, immune enhancing, doses of mtor inhibitors and cars
WO2016014576A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Treatment of cancer using a cd33 chimeric antigen receptor
AU2015292744C1 (en)	2014-07-21	2021-01-21	Novartis Ag	Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3194585A1 (en)	2014-07-21	2017-07-26	Novartis AG	Sortase molecules and uses thereof
EP3174546B1 (en)	2014-07-31	2019-10-30	Novartis AG	Subset-optimized chimeric antigen receptor-containing t-cells
JP6919118B2 (en)	2014-08-14	2021-08-18	ノバルティスアーゲー	Treatment of cancer with GFRα-4 chimeric antigen receptor
RU2020117196A (en)	2014-08-19	2020-10-15	Новартис Аг	CHIMERIC ANTIGENIC RECEPTOR (CAR) AGAINST CD123 FOR USE IN THE TREATMENT OF MALIGNANT TUMORS
ES2891332T3 (en)*	2014-09-17	2022-01-27	Novartis Ag	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN114107424A (en)	2014-10-08	2022-03-01	诺华股份有限公司	Biomarkers for predicting therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
US20170239294A1 (en)	2014-10-15	2017-08-24	Novartis Ag	Compositions and methods for treating b-lymphoid malignancies
WO2016090034A2 (en)*	2014-12-03	2016-06-09	Novartis Ag	Methods for b cell preconditioning in car therapy
CA2972597A1 (en)	2014-12-29	2016-07-07	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
US11459390B2 (en)*	2015-01-16	2022-10-04	Novartis Ag	Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
US11161907B2 (en)*	2015-02-02	2021-11-02	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
US20180140602A1 (en)	2015-04-07	2018-05-24	Novartis Ag	Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
PT3280729T (en)	2015-04-08	2022-08-01	Novartis Ag	Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
JP7114457B2 (en)	2015-04-17	2022-08-08	ザトラスティーズオブザユニバーシティオブペンシルバニア	Methods for Improving Efficacy and Growth of Chimeric Antigen Receptor-Expressing Cells
EP3286211A1 (en)	2015-04-23	2018-02-28	Novartis AG	Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN109476722A (en)*	2015-07-21	2019-03-15	诺华股份有限公司	Methods for improving the efficacy and expansion of immune cells
US11667691B2 (en)	2015-08-07	2023-06-06	Novartis Ag	Treatment of cancer using chimeric CD3 receptor proteins
US11747346B2 (en)	2015-09-03	2023-09-05	Novartis Ag	Biomarkers predictive of cytokine release syndrome
MX2018003353A (en)	2015-09-17	2018-09-17	Novartis Ag	THERAPIES WITH CART CELLS WITH IMPROVED EFFECTIVENESS.
EP3393504B1 (en)	2015-12-22	2025-09-24	Novartis AG	Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
EP3397756B1 (en)	2015-12-30	2023-03-08	Novartis AG	Immune effector cell therapies with enhanced efficacy
EP3523331A1 (en)*	2016-10-07	2019-08-14	Novartis AG	Chimeric antigen receptors for the treatment of cancer
CN109134660B (en)*	2017-06-16	2022-07-01	上海恒润达生生物科技股份有限公司	Methods of targeting chimeric antigen receptors of Mesothelin in combination with expression of anti-PD1 antibodies and uses thereof
CA3090249A1 (en)*	2018-01-31	2019-08-08	Novartis Ag	Combination therapy using a chimeric antigen receptor
US20230297715A1 (en)*	2020-08-06	2023-09-21	Jasmy Incorporated	Terminal device, information processing system and program

2014
- 2014-12-19CACA3225453Apatent/CA3225453A1/enactivePending
- 2014-12-19CNCN201480067596.5Apatent/CN106459989B/enactiveActive
- 2014-12-19EPEP14871351.4Apatent/EP3083964B1/enactiveActive
- 2014-12-19BRBR112016013187Apatent/BR112016013187A2/ennot_activeApplication Discontinuation
- 2014-12-19CACA3225456Apatent/CA3225456A1/enactivePending
- 2014-12-19CNCN202310080668.0Apatent/CN116478927A/enactivePending
- 2014-12-19ESES14871351Tpatent/ES2918501T3/enactiveActive
- 2014-12-19EPEP22152211.3Apatent/EP4026909A1/enactivePending
- 2014-12-19MXMX2016008076Apatent/MX2016008076A/enunknown
- 2014-12-19WOPCT/CN2014/094393patent/WO2015090230A1/enactiveApplication Filing
- 2014-12-19TWTW103144677Apatent/TWI672379B/ennot_activeIP Right Cessation
- 2014-12-19CACA2931684Apatent/CA2931684C/enactiveActive
- 2014-12-19AUAU2014366047Apatent/AU2014366047B2/enactiveActive
- 2014-12-19USUS15/105,082patent/US10640569B2/enactiveActive
- 2014-12-19RURU2016129125Apatent/RU2714902C2/enactive
- 2014-12-19SGSG11201604815RApatent/SG11201604815RA/enunknown
- 2014-12-19JPJP2016541055Apatent/JP6779785B2/enactiveActive
2016
- 2016-05-22ILIL245764Apatent/IL245764A0/enunknown
2020
- 2020-01-23USUS16/750,951patent/US11999794B2/enactiveActive
- 2020-10-14JPJP2020173461Apatent/JP6987945B2/enactiveActive
2021
- 2021-06-01AUAU2021203547Apatent/AU2021203547B2/enactiveActive
- 2021-12-01JPJP2021195532Apatent/JP2022046476A/enactivePending
2023
- 2023-02-16AUAU2023200884Apatent/AU2023200884B2/enactiveActive
- 2023-08-03JPJP2023126889Apatent/JP2023159154A/enactivePending
2024
- 2024-01-31JPJP2024012531Apatent/JP2024050731A/enactivePending
- 2024-03-26AUAU2024201926Apatent/AU2024201926A1/enactivePending
- 2024-04-26USUS18/647,183patent/US20240294662A1/enactivePending
- 2024-08-02USUS18/609,414patent/US20250011461A1/enactivePending

Publication number	Publication date
JP6987945B2 (en)	2022-01-05
BR112016013187A2 (en)	2017-09-26
TW201529850A (en)	2015-08-01
AU2021203547A1 (en)	2021-07-01
CN116478927A (en)	2023-07-25
IL245764A0 (en)	2016-07-31
RU2016129125A (en)	2018-01-23
US10640569B2 (en)	2020-05-05
AU2023200884B2 (en)	2024-05-09
TWI672379B (en)	2019-09-21
CA2931684C (en)	2024-02-20
US20200407460A1 (en)	2020-12-31
US20250011461A1 (en)	2025-01-09
JP2017500869A (en)	2017-01-12
JP2021035948A (en)	2021-03-04
JP2022046476A (en)	2022-03-23
EP3083964B1 (en)	2022-01-26
AU2021203547B2 (en)	2022-11-24
AU2023200884A1 (en)	2023-05-11
CN106459989A (en)	2017-02-22
US11999794B2 (en)	2024-06-04
CA3225456A1 (en)	2015-06-25
JP6779785B2 (en)	2020-11-04
AU2024201926A1 (en)	2024-04-18
JP2024050731A (en)	2024-04-10
CN106459989B (en)	2023-02-17
US20160311917A1 (en)	2016-10-27
EP4026909A1 (en)	2022-07-13
RU2714902C2 (en)	2020-02-20
WO2015090230A1 (en)	2015-06-25
ES2918501T3 (en)	2022-07-18
AU2014366047A1 (en)	2016-06-16
CA3225453A1 (en)	2015-06-25
JP2023159154A (en)	2023-10-31
HK1224332A1 (en)	2017-08-18
EP3083964A1 (en)	2016-10-26
AU2014366047B2 (en)	2021-03-25
MX2016008076A (en)	2016-08-12
US20240294662A1 (en)	2024-09-05
CA2931684A1 (en)	2015-06-25
EP3083964A4 (en)	2017-06-21

Publication	Publication Date	Title
IL245764A0 (en)	2016-07-31	Human mesothelin chimeric antigen receptors and uses thereof
IL272279A (en)	2020-02-27	Chimeric antigen receptor and methods of use thereof
ZA201705720B (en)	2020-02-26	Anti-dll3 chimeric antigen receptors and methods of use
SG11201508805UA (en)	2015-11-27	Cd19 specific chimeric antigen receptor and uses thereof
TWI563003B (en)	2016-12-21	Human anti-il-33 neutralization monoclonal antibody
IL240517A0 (en)	2015-10-29	Anti-b7-h4 antibodies and immunoconjugates
IL243974A0 (en)	2016-04-21	Anti-prlr antibodies and uses thereof
IL240354A0 (en)	2015-09-24	Anti-il-33 antibodies and uses thereof
IL239552B (en)	2019-01-31	Anti-pdgfr-beta antibodies and uses thereof
ZA201703471B (en)	2019-06-26	Anti-cldn chimeric antigen receptors and methods of use
IL243425A0 (en)	2016-03-31	Antibody formulations and methods
SI3026062T1 (en)	2020-12-31	Anti-pd-1 antibody and use thereof
IL241079A0 (en)	2015-11-30	Anti-hepcidin antibodies and uses thereof
IL252604A0 (en)	2017-07-31	Chimeric antigen receptors and their misuse
PL2970492T3 (en)	2019-10-31	Antibodies against human and canine il-13ra2
SI3016977T1 (en)	2020-03-31	Human anti-il-32 antibodies
HK40106034A (en)	2024-08-30	Chimeric antigen receptor and methods of use thereof
ZA201508068B (en)	2021-07-28	Cd19 specific chimeric antigen receptor and uses thereof
HK40013763B (en)	2024-01-12	Chimeric antigen receptor and methods of use thereof

Movatterモバイル変換

SG11201604815RA - Human mesothelin chimeric antigen receptors and uses thereof - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (4)

Publications (1)

Family

ID=53402126

Family Applications (1)

Country Status (14)

Families Citing this family (169)

Family Cites Families (255)

Also Published As

Similar Documents